gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Clinical phase I/II trial to assess antitumor activity and tolerability of dacarbazine i.v. plus Imatinib (Glivec) orally in patients with metastatic malignant melanoma

Meeting Abstract

Search Medline for

  • corresponding author presenting/speaker Karsten Neuber - Universitätsklinikum Hamburg-Eppendorf, Deutschland
  • Almuth Boecker - Universitätsklinikum Hamburg-Eppendorf

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO613

The electronic version of this article is the complete one and can be found online at:

Published: March 20, 2006

© 2006 Neuber et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



At present, no treatment options are available for melanoma patients with advanced metastatic disease that provide either sufficient response rates or a significant prolongation of survival. Chemotherapy with dacarbacine (DTIC) does actually apply as the standard treatment regimen in advanced melanoma, leading to response rates between 9.9 and 18%. Imatinib inhibits selectively several tyrosine kinases, e.g. Abl, Kit, and platelet-derived growth factor receptors (PDGF-R), which have been shown to be expressed by melanoma cells. Used as a single agent in metastatic melanoma patients imatinib was not efficient. Therefore, a combination of DTIC (800 mg/m2 i.v., days 1 und 28) and Imatinib (400 mg/d p.os, days 2-27 and days 29-56) was studied in this clinical trial as a first-line treatment. In 15 evaluable patients no objective responses could be observed. Two patients (13.3%) had a stable disease and 13 patients (86.7%) had progressive disease. The median overall survival was 6 months (95% CI 2.88; 9.12 months), the median time to progression was 2 months. No grade 3 or 4 toxicity was observed using this combination treatment. In conclusion, DTIC and Imatinib is a well tolerated regimen. However, this study did not reveal an efficacy of imatinib combined with DTIC in metastatic melanoma.